CNTF, STAT3 and new therapies for axonal degeneration: what are they and what can they do?

Author： Selvaraj Bhuvaneish Thangaraj   Sendtner Michael  

Publisher： Informa Healthcare

ISSN： 1473-7175

Source： Expert Review of Neurotherapeutics, Vol.13, Iss.3, 2013-03, pp. : 239-241

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prevention and Pharmacovigilance: What Should We Do, What Can We Do?

By Edwards I. Ralph  

Drug Safety, Vol. 35, Iss. 2, 2012-02 ,pp. : 87-90

Adis International

Access to resources Recommend Favorite

The diabetic heart - what is to blame and what can we do?

By  

Inpharma, Vol. 1, Iss. 1302, 2001-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?

By Sahebkar Amirhossein   Watts Gerald  

Cardiovascular Drugs and Therapy, Vol. 27, Iss. 6, 2013-12 ,pp. : 559-567

Springer Publishing Company

Access to resources Recommend Favorite

Combined Opioid-NMDA Antagonist Therapies: What Advantages Do They Offer for the Control of Pain Syndromes?

By Wiesenfeld-Hallin Z.  

Drugs, Vol. 55, Iss. 1, 1998-01 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

What the PDI Can Do for Oral Health

By  

Journal of Prosthodontics, Vol. 20, Iss. 2, 2011-02 ,pp. : 81-82

Blackwell Publishing

Access to resources Recommend Favorite